← Leaderboards
Stephen J Bernard
University Of North Carolina Chapel Hill
$0
Attributed
$0
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 4
By mechanism
M01$0 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Matthew J Ewend$6,239,820
- Stephen Bernard$2,912,053
- Wendell G Yarbrough$10,193,706
- Randall J Kimple$6,527,333
- Thomas Shea$5,623,497
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationDrug Adverse EffectNeoplasm /Cancer ChemotherapyQuality Of LifeAntineoplasticsXerostomiasClinical Trial Phase IDrug Administration Rate /DurationGlioblastoma MultiformeHead /Neck NeoplasmIntravenous AdministrationNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer Relapse /RecurrenceOral AdministrationProcarbazineRadiobiologyRecombinant ProteinsFibroblast Growth FactorColorectal NeoplasmsEstrogen InhibitorFemale
Grant awards (8)
RHUKGF IN HEAD &NECK CANCER PATIENTS$0
M01 · FY2000 · RR
RHUKGF IN HEAD &NECK CANCER PATIENTS$0
M01 · FY2000 · RR
RHUKGF IN HEAD &NECK CANCER PATIENTS$0
M01 · FY2000 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$0
M01 · FY2000 · RR
SU101 VS PROCARBAZINE FOR GLIOBLASTOMA MULTIFORME PTS$0
M01 · FY2000 · RR
SU101 VS PROCARBAZINE FOR GLIOBLASTOMA MULTIFORME PTS$0
M01 · FY2000 · RR
SU101 VS PROCARBAZINE FOR GLIOBLASTOMA MULTIFORME PTS$0
M01 · FY2000 · RR
TAMOXIFEN &RALOXIFENE FOR PREVENTTION OF BREAST CANCER$0
M01 · FY2000 · RR